Latest Schedule 13G passive stakes

AQR Capital Management, through its affiliates, has reported beneficial ownership of 5.13% of Roman DBDR Acquisition Corp. II's Class A ordinary shares as of June 30, 2026.

AQR Capital Management, through its subsidiaries, has reported beneficial ownership of 4.63% of Paloma Acquisition Corp I's Class A ordinary shares as of June 30, 2026.

A group of Ameriprise Financial entities has disclosed a combined beneficial ownership of 17.7% of Empire State Realty Trust's Class A Common Stock.

A group of Ameriprise Financial entities has disclosed a combined beneficial ownership of 17.7% of Empire State Realty Trust's Class A Common Stock.

AQR Capital Management entities report a beneficial ownership of 7.02% in Spark I Acquisition Corp's Class A ordinary shares as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 167,513 ordinary shares, representing 4.99% of Wearable Devices Ltd.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,436,000 shares, representing 5.58% of Voyager Therapeutics, Inc.'s common stock, as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Vivos Therapeutics, Inc. common stock as of June 30, 2026.

Howard Lee and associated entities have filed an exit statement for Lucas GC Ltd, reporting beneficial ownership below the 5% threshold.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 7,024,000 shares, representing 7.76% of Verastem, Inc.'s common stock, as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 4,079,129 shares, representing 7.33% of VSee Health, Inc.'s common stock.

Ameriprise Financial and Columbia Management report a combined 10.6% beneficial ownership of Hamilton Beach Brands Holding Company's Class A Common Stock as of June 30, 2026.

Ameriprise Financial and Columbia Management report a combined 10.6% beneficial ownership of Hamilton Beach Brands Holding Company's Class A Common Stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 1,572,539 shares, representing 1.67% of the outstanding common stock of Travere Therapeutics, Inc.

Armistice Capital, LLC and Steven Boyd report acquiring a 9.91% beneficial ownership stake in Trevena, Inc., holding 95,000 shares.

Armistice Capital, LLC, along with Steven Boyd, has reported beneficial ownership of 54,554 shares, representing 9.99% of the common stock of Tenon Medical, Inc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 6,364,000 shares, representing 9.79% of the common stock of Treace Medical Concepts, Inc.

Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 9.99% in Stryve Foods, Inc. Class A Common Stock.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.38% of Sangamo Therapeutics, Inc.'s common stock, filing as a Schedule 13G.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 3,328,000 shares, representing 7.29% of Rapid Micro Biosystems, Inc.'s Class A common stock.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting a beneficial ownership of 9.99% in Arcadia Biosciences, Inc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares, representing 8.95% of Rigel Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Ameriprise Financial, Inc. and its subsidiary Ameriprise Financial Services, LLC have reported beneficial ownership of 6.7% of Nuveen Mortgage and Income Fund's common stock.

Ameriprise Financial, Inc. and its subsidiary Ameriprise Financial Services, LLC have reported beneficial ownership of 6.7% of Nuveen Mortgage and Income Fund's common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Revelation Biosciences, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 83,769 shares, representing 9.99% of PowerCompute, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 1,531,152 shares, representing 8.58% of The OLB Group, Inc.'s common stock.

Skandinaviska Enskilda Banken AB (publ) has filed a Schedule 13G, disclosing beneficial ownership of 5.3% of Autoliv Inc.'s common stock represented by Swedish Depositary Receipts.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,264,000 shares, representing 8.01% of Orthofix Medical Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have updated their beneficial ownership filing for Nuwellis, Inc., reporting a 4.99% stake.